Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy

Hye Young Wang, Sungwoo Ahn, Sunghyun Kim, Sunyoung Park, Sangjung Park, Hyunju Han, Joo Hyuk Sohn, Seung Il Kim, Hyeyoung Lee

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Circulating tumor cells (CTCs) are an independent prognostic factor for patients with breast cancer. However, the role of CTCs in early breast cancer management is not yet clearly defined. The aim of this study was to isolate and characterize CTCs in blood sample of a breast cancer patient as a biomarker for monitoring treatments efficacy. In this study, 692 blood samples from 221 breast cancer patients and 376 healthy individuals was used to detect CTCs with multiple markers including epithelial cell adhesion molecule (EpCAM), cytokeratin (CK) 19, human epidermal growth factor (HER) 2, Ki67, human telomerase reverse transcriptase (hTERT), and vimentin using quantitative reverse transcription PCR (RT-qPCR). A total of 153 (69.2%) blood samples of 221 patients with breast cancer were found to be positive for at least one of the cancer-associated marker gene before treatment. After chemotherapy, no CTCs were found in 28 (33.3%) of the 84 blood samples analyzed for the presence of CTCs using the RT-qPCR, whereas 56 (66.7%) blood samples were still found to be positive for at least one of the markers. After completing the therapy, the CTC positivity rate decreased to 7 (20.6%) in the neoadjuvant group, whereas this increased to 7 (14%) cases in the adjuvant group. There was no statistically significant relationship between TNM stage and detection of CTC-related markers. Data from this study suggest that RT-qPCR assay for the detection of CTC markers might be useful in selecting appropriate therapeutics and for monitoring treatment efficacy in breast cancer patients.

Original languageEnglish
Pages (from-to)445-452
Number of pages8
JournalExperimental and Molecular Pathology
Volume97
Issue number3
DOIs
Publication statusPublished - 2014 Dec 1

Fingerprint

Circulating Neoplastic Cells
Tumors
Assays
Cells
Breast Neoplasms
Polymerase Chain Reaction
Monitoring
Blood
Therapeutics
Keratin-19
Chemotherapy
Cell Adhesion Molecules
Biomarkers
Vimentin
Transcription
Tumor Biomarkers
Epidermal Growth Factor
Reverse Transcription
Genes
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Wang, Hye Young ; Ahn, Sungwoo ; Kim, Sunghyun ; Park, Sunyoung ; Park, Sangjung ; Han, Hyunju ; Sohn, Joo Hyuk ; Kim, Seung Il ; Lee, Hyeyoung. / Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy. In: Experimental and Molecular Pathology. 2014 ; Vol. 97, No. 3. pp. 445-452.
@article{feeae65e86b746cb95d58571e81e2fa3,
title = "Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy",
abstract = "Circulating tumor cells (CTCs) are an independent prognostic factor for patients with breast cancer. However, the role of CTCs in early breast cancer management is not yet clearly defined. The aim of this study was to isolate and characterize CTCs in blood sample of a breast cancer patient as a biomarker for monitoring treatments efficacy. In this study, 692 blood samples from 221 breast cancer patients and 376 healthy individuals was used to detect CTCs with multiple markers including epithelial cell adhesion molecule (EpCAM), cytokeratin (CK) 19, human epidermal growth factor (HER) 2, Ki67, human telomerase reverse transcriptase (hTERT), and vimentin using quantitative reverse transcription PCR (RT-qPCR). A total of 153 (69.2{\%}) blood samples of 221 patients with breast cancer were found to be positive for at least one of the cancer-associated marker gene before treatment. After chemotherapy, no CTCs were found in 28 (33.3{\%}) of the 84 blood samples analyzed for the presence of CTCs using the RT-qPCR, whereas 56 (66.7{\%}) blood samples were still found to be positive for at least one of the markers. After completing the therapy, the CTC positivity rate decreased to 7 (20.6{\%}) in the neoadjuvant group, whereas this increased to 7 (14{\%}) cases in the adjuvant group. There was no statistically significant relationship between TNM stage and detection of CTC-related markers. Data from this study suggest that RT-qPCR assay for the detection of CTC markers might be useful in selecting appropriate therapeutics and for monitoring treatment efficacy in breast cancer patients.",
author = "Wang, {Hye Young} and Sungwoo Ahn and Sunghyun Kim and Sunyoung Park and Sangjung Park and Hyunju Han and Sohn, {Joo Hyuk} and Kim, {Seung Il} and Hyeyoung Lee",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.yexmp.2014.09.003",
language = "English",
volume = "97",
pages = "445--452",
journal = "Experimental and Molecular Pathology",
issn = "0014-4800",
publisher = "Academic Press Inc.",
number = "3",

}

Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy. / Wang, Hye Young; Ahn, Sungwoo; Kim, Sunghyun; Park, Sunyoung; Park, Sangjung; Han, Hyunju; Sohn, Joo Hyuk; Kim, Seung Il; Lee, Hyeyoung.

In: Experimental and Molecular Pathology, Vol. 97, No. 3, 01.12.2014, p. 445-452.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Detection of circulating tumor cells in patients with breast cancer using the quantitative RT-PCR assay for monitoring of therapy efficacy

AU - Wang, Hye Young

AU - Ahn, Sungwoo

AU - Kim, Sunghyun

AU - Park, Sunyoung

AU - Park, Sangjung

AU - Han, Hyunju

AU - Sohn, Joo Hyuk

AU - Kim, Seung Il

AU - Lee, Hyeyoung

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Circulating tumor cells (CTCs) are an independent prognostic factor for patients with breast cancer. However, the role of CTCs in early breast cancer management is not yet clearly defined. The aim of this study was to isolate and characterize CTCs in blood sample of a breast cancer patient as a biomarker for monitoring treatments efficacy. In this study, 692 blood samples from 221 breast cancer patients and 376 healthy individuals was used to detect CTCs with multiple markers including epithelial cell adhesion molecule (EpCAM), cytokeratin (CK) 19, human epidermal growth factor (HER) 2, Ki67, human telomerase reverse transcriptase (hTERT), and vimentin using quantitative reverse transcription PCR (RT-qPCR). A total of 153 (69.2%) blood samples of 221 patients with breast cancer were found to be positive for at least one of the cancer-associated marker gene before treatment. After chemotherapy, no CTCs were found in 28 (33.3%) of the 84 blood samples analyzed for the presence of CTCs using the RT-qPCR, whereas 56 (66.7%) blood samples were still found to be positive for at least one of the markers. After completing the therapy, the CTC positivity rate decreased to 7 (20.6%) in the neoadjuvant group, whereas this increased to 7 (14%) cases in the adjuvant group. There was no statistically significant relationship between TNM stage and detection of CTC-related markers. Data from this study suggest that RT-qPCR assay for the detection of CTC markers might be useful in selecting appropriate therapeutics and for monitoring treatment efficacy in breast cancer patients.

AB - Circulating tumor cells (CTCs) are an independent prognostic factor for patients with breast cancer. However, the role of CTCs in early breast cancer management is not yet clearly defined. The aim of this study was to isolate and characterize CTCs in blood sample of a breast cancer patient as a biomarker for monitoring treatments efficacy. In this study, 692 blood samples from 221 breast cancer patients and 376 healthy individuals was used to detect CTCs with multiple markers including epithelial cell adhesion molecule (EpCAM), cytokeratin (CK) 19, human epidermal growth factor (HER) 2, Ki67, human telomerase reverse transcriptase (hTERT), and vimentin using quantitative reverse transcription PCR (RT-qPCR). A total of 153 (69.2%) blood samples of 221 patients with breast cancer were found to be positive for at least one of the cancer-associated marker gene before treatment. After chemotherapy, no CTCs were found in 28 (33.3%) of the 84 blood samples analyzed for the presence of CTCs using the RT-qPCR, whereas 56 (66.7%) blood samples were still found to be positive for at least one of the markers. After completing the therapy, the CTC positivity rate decreased to 7 (20.6%) in the neoadjuvant group, whereas this increased to 7 (14%) cases in the adjuvant group. There was no statistically significant relationship between TNM stage and detection of CTC-related markers. Data from this study suggest that RT-qPCR assay for the detection of CTC markers might be useful in selecting appropriate therapeutics and for monitoring treatment efficacy in breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84908106231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908106231&partnerID=8YFLogxK

U2 - 10.1016/j.yexmp.2014.09.003

DO - 10.1016/j.yexmp.2014.09.003

M3 - Article

C2 - 25217799

AN - SCOPUS:84908106231

VL - 97

SP - 445

EP - 452

JO - Experimental and Molecular Pathology

JF - Experimental and Molecular Pathology

SN - 0014-4800

IS - 3

ER -